It has to be noted that the A2AR agonist CGS 21680 only conferred protection when being chronically administered, whereas delivery limited to the first 24 h after stroke did not reduce infarct volume [169] as it probably missed the peak of immune cell infiltration at day 3 after tMCAO [170]. The gene discussed is ADORA2A; the disease is Stroke.